All data are based on the daily closing price as of July 11, 2025
h
Hanmi Pharm. Co.
128940.KO
207.70 USD
-0.84
-0.40%
Overview
Last close
207.70 usd
Market cap
2.63B usd
52 week high
258.79 usd
52 week low
146.58 usd
Target price
259.1 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
2.4415
Price/Book Value
3.2545
Enterprise Value
2.82B usd
EV/Revenue
2.617
EV/EBITDA
14.3721
Key financials
Revenue TTM
1.08B usd
Gross Profit TTM
585.01M usd
EBITDA TTM
212.79M usd
Earnings per Share
N/A usd
Dividend
0.91 usd
Total assets
1.35B usd
Net debt
N/A usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.